<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01112371</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ 90011_4023_1</org_study_id>
    <nct_id>NCT01112371</nct_id>
  </id_info>
  <brief_title>Contractubex Treatment in Scars After Abdominal Caesarean Section</brief_title>
  <acronym>ConMex</acronym>
  <official_title>A Prospective, Single-center, Randomized, Parallel Group Trial to Investigate the Efficacy of Contractubex® Gel, Containing Extractum Cepae, Allantoin, and Heparin, in Scars After Abdominal Caesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of Contractubex® Gel, containing&#xD;
      extractum cepae, allantoin and heparin, in the treatment of scars after abdominal Caesarean&#xD;
      section compared to untreated scars after abdominal Caesarean section.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Appearance of the scars will be evaluated by use of the Patient and Observer Scar Assessment Scale [POSAS].</measure>
    <time_frame>Screening and 12 weeks</time_frame>
    <description>The scale consists of two numeric scales which need to be filled out by the observer and the patient, respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appearance of the scars will be evaluated by use of the Patient and Observer Scar Assessment Scale [POSAS].</measure>
    <time_frame>Screening and 6 weeks</time_frame>
    <description>The scale consists of two numeric scales which need to be filled out by the observer and the patient, respectively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Scars</condition>
  <arm_group>
    <arm_group_label>Contractubex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Contractubex</intervention_name>
    <description>Contractubex® Gel, containing 10% extractum cepae, 1% allantoin and 50/U of sodium heparin per one gram of gel.&#xD;
Active drug group: The gel will be applied twice daily (morning/evening). Approximately 2 cm of the IMP are applied onto the scar by light massage rubbing carefully until the product is worked in.</description>
    <arm_group_label>Contractubex</arm_group_label>
    <other_name>Other names have not been specified.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females having given birth via elective abdominal Caesarean section for the first time&#xD;
             within the last 5 to 10 days who had their suture removed (removed at screening).&#xD;
&#xD;
          -  Age: 18 years or older.&#xD;
&#xD;
          -  The subject must be willing and must be able to complete the entire course of the&#xD;
             trial and to comply with the trial instructions.&#xD;
&#xD;
          -  Written informed consent has been obtained from the subject.&#xD;
&#xD;
          -  Females using suitable contraceptions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any inadmissible medication, e.g. systemic corticosteroids, systemic&#xD;
             immunosuppressants (such as cytostatics, therapy with antibodies, biologics,&#xD;
             interferone, mykophenolatmofetil, methotrexate, cyclosporine, azathioprine). Any&#xD;
             additional topical treatment in the area of the lower abdomen, regardless of the mode&#xD;
             of action.&#xD;
&#xD;
          -  Any other planned topical treatment in the lower part of the abdomen during the course&#xD;
             of the trial.&#xD;
&#xD;
          -  Any infection or wound in the area to treat.&#xD;
&#xD;
          -  History of keloids or hypertrophic scars.&#xD;
&#xD;
          -  Any severe or uncontrolled systemic disease (e.g. cardiac, renal, pulmonary, hepatic,&#xD;
             or gastrointestinal), malignant tumor, or medical history of HIV infection.&#xD;
&#xD;
          -  Any tumor diseases in the abdominal region independent of their dignity.&#xD;
&#xD;
          -  Females having given birth via emergency abdominal Caesarean section.&#xD;
&#xD;
          -  Psychiatric problems which, in the investigator's opinion, are severe enough to&#xD;
             interfere with the trial results.&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days prior to screening.&#xD;
&#xD;
          -  Evidence or suspicion that the subject might not comply with the study directives&#xD;
             and/or that she is not reliable or trustworthy.&#xD;
&#xD;
          -  Evidence or suspicion that the subject is not willing or unable to understand the&#xD;
             information given to her as part of the informed consent, in particular regarding the&#xD;
             risks and discomfort to which she would agree to be exposed.&#xD;
&#xD;
          -  Previous participation in this clinical study.&#xD;
&#xD;
          -  Known allergy or hypersensitivity to the study drug(s) or one of the ingredients of&#xD;
             the formulation.&#xD;
&#xD;
          -  Subjects who are imprisoned or are lawfully kept in an institution.&#xD;
&#xD;
          -  Employees or direct relatives of an employee of the CRO, the study center or Merz&#xD;
             Pharmaceuticals.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Ocampo Candiani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jefe del Departamento Dermatologia, Facultad de medicina y Hospital Universitario, Universidad Autonoma de Nuevo León, Monterrey Nuevo León,C.P. 64460, Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jefe del Departamento Dermatologia, Facultad de medicina y Hospital Universitario, Universidad Autonoma de Nuevo León</name>
      <address>
        <city>Monterrey Nuevo León</city>
        <state>C.p.</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Ocampo-Candiani J, et al. Efficacy of a topical gel containing extractum cepae, allantoin and heparin in the treatment of abdominal caesarean section scars. IMCAS Annual Meeting 2013. www.imcas.com/en/imcas2013/schedule/lecture/id/5971</citation>
  </results_reference>
  <results_reference>
    <citation>Ocampo-Candiani J, Vázquez-Martínez OT, Iglesias Benavides JL, Buske K, Lehn A, Acker C. The prophylactic use of a topical scar gel containing extract of Allium cepae, allantoin, and heparin improves symptoms and appearance of cesarean-section scars compared with untreated scars. J Drugs Dermatol. 2014 Feb;13(2):176-82.</citation>
    <PMID>24509969</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>April 6, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2010</study_first_posted>
  <last_update_submitted>April 7, 2014</last_update_submitted>
  <last_update_submitted_qc>April 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>scars after abdominal Caesarean section</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

